- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02971150
Treatment Resistant Depression and Insomnia in Older Veterans
Treatment Resistant Depression and Insomnia in Older Veterans: A Pilot Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Quantitative and qualitative methods will be used to obtain information to aid in developing treatment approaches appropriate for older Veterans with TRD and insomnia. Qualitative data will be gathered to better understand Veterans' preferences for treatment approaches, particularly relating to preference for pharmacotherapy versus augmentation with a behavioral intervention such as BBTI. Using a Randomized Controlled Trial (RCT) design, we will test whether augmentation with BBTI will be acceptable to older Veterans and improve treatment response in those whose depression has not improved with antidepressant pharmacotherapy alone and assess for an association between preference and treatment response. Our aims and hypotheses are:
Aim 1: To characterize the depression, insomnia, and relevant clinical and neuropsychiatric characteristics of older Veterans with TRD.
H1a: In Veterans with TRD, Antidepressant History Form (ATHF) scores will have a positive association with Montgomery-Asberg Depression Rating scale (MADRS) scores.
H1b: In Veterans with TRD, MADRS scores will have a positive association with Insomnia Severity Index (ISI) scores.
Aim 2: Perform qualitative interviews in older Veterans to collect information about their views of their depression and insomnia and attitudes and preferences for treatment of both depression and insomnia.
Aim 3: To examine the feasibility of using BBTI to treat Veterans with TRD and insomnia.
H3a: Use of BBTI will be feasible in older adults with TRD as defined by acceptability and retention.
Aim 4: To determine if antidepressant augmentation with BBTI leads to improvement in scores on MADRS and ISI scales in older Veterans receiving BBTI versus those receiving only antidepressant optimization.
H4a: Augmentation with BBTI will improve both PHQ-9 and ISI scores relative treatment with antidepressant alone.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15240
- VA Pittsburgh Healthcare System
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥ 60
- Diagnosis of Major Depressive Disorder (MDD)
- Diagnosis of Insomnia Disorder
- Must have failed ≥ 1 antidepressant trial
Exclusion Criteria:
- Lifetime/current Bipolar I/II diagnosis
- Lifetime/current Schizophrenia Spectrum Disorder diagnosis
- Substance Use Disorder within past 3 months
- High Suicide Risk that cannot be safely managed
- Untreated Obstructive Sleep Apnea (OSA)
- Restless Legs Syndrome
- Rapid Eye Movement (REM) Sleep Behavior Disorder
- Active OR untreated Post Traumatic Stress Disorder (PTSD)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: BBTI
Participants will receive Brief Behavioral Treatment for Insomnia (BBTI).
This will be administered over the course of 4 weeks.
BBTI is based on the concepts of sleep restriction and stimulus control.
The first and third session are in person and the 2 and 4th session are conducted over the phone.
Throughout the treatment, participants will complete daily sleep dairies.
After 4 weeks of treatment, participants randomized to this group will cross over to the no intervention group and will be called once a week to assess mood and sleep symptoms.
|
Other Names:
|
|
NO_INTERVENTION: Control
Participants will not receive treatment.
They will be contacted by phone once a week to complete assessments of mood and sleep.
After 4 weeks, they will cross over to the experimental BBTI group.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
PHQ-9 ( depression)
Time Frame: 8 weeks
|
8 weeks
|
|
ISI score ( insomnia)
Time Frame: 8 weeks
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Short Form Survey (SF-12) SF-12 ( quality of life)
Time Frame: 8 weeks
|
8 weeks
|
|
Emotional Closeness Questionnaire ( ECQ)
Time Frame: 8 weeks
|
8 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PRO0001567
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.